Sector Gamma As
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 12, 2026), Sector Gamma As reported 40 stock positions worth $461.0 million. Its top holding was Bristol-Myers Squibb (BMY) at 9.1% of the portfolio, followed by Merck (MRK, 6.0%) and Medtronic (MDT, 6.0%). Compared with Q1 2026, it opened 6 new positions, sold out of 8, added to 19 and reduced 11. The biggest buy was a new position in Thermo Fisher Scientific (TMO) and the biggest sale Bristol-Myers Squibb (BMY, shares −12%).
- Most Recent 13F
- Q2 2026
- Location
- OSLO, Q8
- CIK
- 0001475373
- Portfolio Value
- $461.0M (Q2 2026)
- SEC Filing
- 0000945621-26-001027 ↗ filed Aug 12, 2026
Holdings Value
Holdings 40 stocks · $461.0M
| BMY Bristol-Myers Squibb Co. | 9.08% | 726,115 | $41.8M | Reduce -12.3% |
| MRK Merck & Co. Inc. | 6.05% | 217,008 | $27.9M | Reduce -16.6% |
| MDT Medtronic PLC | 5.98% | 352,437 | $27.6M | Add +25.6% |
| PFE Pfizer Inc. | 5.25% | 1,004,215 | $24.2M | Reduce -8.0% |
| INCY Incyte Corp. | 4.20% | 170,753 | $19.4M | Reduce -14.8% |
| ELV Elevance Health Inc. | 3.73% | 44,499 | $17.2M | Add +1.2% |
| BMRN Biomarin Pharmaceutical Inc. | 3.66% | 294,918 | $16.9M | Add +22.9% |
| TMO Thermo Fisher Scientific Inc. | 3.65% | 33,584 | $16.8M | New |
| CVS CVS Health Corp. | 3.49% | 155,337 | $16.1M | Add +14.8% |
| IQV Iqvia Holdings Inc. | 3.27% | 77,944 | $15.1M | Add +93.8% |
| IONS Ionis Pharmaceuticals Inc. | 3.26% | 189,468 | $15.0M | Add +11.8% |
| BDX Becton Dickinson and Co. | 3.06% | 93,168 | $14.1M | Add +12.8% |
| ABT Abbott Laboratories | 2.90% | 147,444 | $13.4M | Add +68.5% |
| GEHC GE Healthcare Technology | 2.89% | 207,863 | $13.3M | Add +64.4% |
| ZBH Zimmer Biomet Holdings Inc. | 2.66% | 142,307 | $12.3M | Reduce -8.7% |
| BIIB Biogen Inc. | 2.54% | 54,163 | $11.7M | Reduce -39.9% |
| QGEN Qiagen N.V. | 2.44% | 287,640 | $11.2M | Add +77.2% |
| CNC Centene Corp. | 2.26% | 162,405 | $10.4M | No change |
| REGN Regeneron Pharmaceuticals | 2.13% | 15,780 | $9.8M | New |
| BIO Bio-Rad Laboratories-A | 2.12% | 33,350 | $9.8M | Add +40.4% |
| CAH Cardinal Health Inc. | 2.10% | 40,689 | $9.7M | Reduce -25.9% |
| AMGN Amgen Inc. | 2.06% | 26,281 | $9.5M | Reduce -44.3% |
| BRKR Bruker Corp. | 1.99% | 152,352 | $9.2M | Reduce -40.0% |
| AVTR Avantor Inc. | 1.95% | 906,088 | $9.0M | Add +30.3% |
| PTCT PTC Therapeutics Inc. | 1.77% | 100,000 | $8.2M | Add +33.3% |
| LH Labcorp Holdings Inc. | 1.58% | 26,019 | $7.3M | Add +36.8% |
| DXCM Dexcom Inc. | 1.49% | 102,122 | $6.9M | Add +82.0% |
| ASND Ascendis Pharma A/S | 1.23% | 21,305 | $5.7M | No change |
| EW Edwards Lifesciences Corp. | 1.19% | 60,402 | $5.5M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 1.15% | 241,739 | $5.3M | Reduce -15.5% |
| BSX Boston Scientific Corp. | 1.12% | 121,128 | $5.2M | New |
| KURA Kura Oncology Inc. | 1.03% | 433,012 | $4.8M | Add +5.2% |
| TVTX Travere Therapeutics Inc. | 0.99% | 80,000 | $4.5M | New |
| CRNX Crinetics Pharmaceuticals Inc. | 0.93% | 114,628 | $4.3M | Add +21.7% |
| TNDM Tandem Diabetes Care Inc. | 0.87% | 267,091 | $4.0M | No change |
| IOVA Iovance Biotherapeutics Inc. | 0.87% | 968,466 | $4.0M | Add +7.6% |
| CYTK Cytokinetics Inc. | 0.83% | 45,000 | $3.8M | New |
| OGN Organon & Co. | 0.80% | 270,781 | $3.7M | Reduce -28.0% |
| ARDX Ardelyx Inc. | 0.76% | 686,844 | $3.5M | Add +33.1% |
| NTLA Intellia Therapeutics Inc. | 0.68% | 185,177 | $3.1M | New |
Portfolio Sells Q1 2026 → Q2 2026
| BMY Bristol-Myers Squibb Co. | Reduce -12.3% | 9.08% | −2.78 |
| UNH Unitedhealth Group Inc. | Sold out | 0.00% | −2.33 |
| PFE Pfizer Inc. | Reduce -8.0% | 5.25% | −1.99 |
| AMGN Amgen Inc. | Reduce -44.3% | 2.06% | −1.85 |
| GILD Gilead Sciences Inc. | Sold out | 0.00% | −1.75 |
| LNTH Lantheus Holdings Inc. | Sold out | 0.00% | −1.67 |
| BIIB Biogen Inc. | Reduce -39.9% | 2.54% | −1.36 |
| MRK Merck & Co. Inc. | Reduce -16.6% | 6.05% | −1.35 |
| HUM Humana Inc. | Sold out | 0.00% | −0.79 |
| BBIO Bridgebio Pharma Inc. | Sold out | 0.00% | −0.78 |
| DNLI Denali Therapeutics Inc. | Sold out | 0.00% | −0.74 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −0.73 |
| ZBH Zimmer Biomet Holdings Inc. | Reduce -8.7% | 2.66% | −0.67 |
| CAH Cardinal Health Inc. | Reduce -25.9% | 2.10% | −0.64 |
| ARWR Arrowhead Pharmaceuticals Inc. | Sold out | 0.00% | −0.44 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -15.5% | 1.15% | −0.43 |
| INCY Incyte Corp. | Reduce -14.8% | 4.20% | −0.26 |
| BRKR Bruker Corp. | Reduce -40.0% | 1.99% | −0.18 |
| OGN Organon & Co. | Reduce -28.0% | 0.80% | +0.26 |
Portfolio Buys Q1 2026 → Q2 2026
| TMO Thermo Fisher Scientific Inc. | New | 3.65% | +3.65 |
| REGN Regeneron Pharmaceuticals | New | 2.13% | +2.13 |
| IQV Iqvia Holdings Inc. | Add +93.8% | 3.27% | +1.65 |
| CVS CVS Health Corp. | Add +14.8% | 3.49% | +1.19 |
| BSX Boston Scientific Corp. | New | 1.12% | +1.12 |
| TVTX Travere Therapeutics Inc. | New | 0.99% | +0.99 |
| QGEN Qiagen N.V. | Add +77.2% | 2.44% | +0.90 |
| CYTK Cytokinetics Inc. | New | 0.83% | +0.83 |
| ABT Abbott Laboratories | Add +68.5% | 2.90% | +0.78 |
| GEHC GE Healthcare Technology | Add +64.4% | 2.89% | +0.76 |
| ELV Elevance Health Inc. | Add +1.2% | 3.73% | +0.69 |
| NTLA Intellia Therapeutics Inc. | New | 0.68% | +0.68 |
| DXCM Dexcom Inc. | Add +82.0% | 1.49% | +0.66 |
| AVTR Avantor Inc. | Add +30.3% | 1.95% | +0.66 |
| PTCT PTC Therapeutics Inc. | Add +33.3% | 1.77% | +0.56 |
| BIO Bio-Rad Laboratories-A | Add +40.4% | 2.12% | +0.56 |
| BMRN Biomarin Pharmaceutical Inc. | Add +22.9% | 3.66% | +0.46 |
| LH Labcorp Holdings Inc. | Add +36.8% | 1.58% | +0.38 |
| IONS Ionis Pharmaceuticals Inc. | Add +11.8% | 3.26% | +0.25 |
| KURA Kura Oncology Inc. | Add +5.2% | 1.03% | +0.24 |
| MDT Medtronic PLC | Add +25.6% | 5.98% | +0.24 |
| IOVA Iovance Biotherapeutics Inc. | Add +7.6% | 0.87% | +0.13 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +21.7% | 0.93% | +0.12 |
| ARDX Ardelyx Inc. | Add +33.1% | 0.76% | +0.03 |
| BDX Becton Dickinson and Co. | Add +12.8% | 3.06% | −0.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 40 | $461.0M | BMY, MRK, MDT, PFE, INCY |
| Q1 2026 | 42 | $423.5M | BMY, MRK, PFE, MDT, INCY |
| Q4 2025 | 36 | $438.7M | BMY, MRK, MDT, BDX, GILD |
| Q3 2025 | 41 | $403.3M | PFE, MDT, MRK, BMY, BDX |
| Q2 2025 | 38 | $305.9M | PFE, MDT, BMY, BDX, MRK |
| Q1 2025 | 33 | $312.2M | BMY, PFE, BDX, MDT, AMGN |
| Q4 2024 | 30 | $290.9M | PFE, MDT, BMY, GILD, BDX |
| Q3 2024 | 29 | $329.6M | BMY, MDT, GILD, PFE, CVS |
| Q2 2024 | 28 | $267.7M | GILD, PFE, BMY, MDT, ELV |
| Q1 2024 | 28 | $354.8M | MDT, PFE, BMY, CVS, CAH |